Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 5/20 | 0.61 |
| ▸ | CA4 | P22748 | 4/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942822 | 1.00 | CA1 (0.61) | CA1CA2CA4NFKB1HCAR2 | |
| SCHEMBL4543959 | 0.88 | NFKB1 (0.69) | CA1CA2CA4NFKB1HCAR2 | |
| SCHEMBL3423203 | 0.88 | NFKB1 (0.69) | CA1CA2CA4NFKB1HCAR2 | |
| SCHEMBL21224294 | 0.86 | MAOB (0.58) | CA1CA2CA4NFKB1HCAR2 | |
| SCHEMBL31071896 | 0.86 | MAOB (0.58) | CA1CA2CA4NFKB1HCAR2 | |
| SCHEMBL11834874 | 0.86 | CA1 (0.52) | CA1CA2CA4NFKB1HCAR2 | |
| SCHEMBL31501089 | 0.82 | BACE1 (0.59) | CA1CA2CA4NFKB1CA12 | |
| SCHEMBL6857696 | 0.80 | MAPT (0.59) | CA1CA2CA4NFKB1KDM4E | |
| SCHEMBL6857698 | 0.80 | MAPT (0.59) | CA1CA2CA4NFKB1KDM4E | |
| SCHEMBL8746642 | 0.77 | CA1 (0.61) | CA1CA2CA4NFKB1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS INC. | 2024-09-03 | — | — | US | claimed |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-31 | — | — | US | claimed |
| US-11234975-B2 | Levorphanol prodrugs and processes for making and using them | KEMPHARM, INC. (US) | 2022-02-01 | — | — | US | claimed |
| US-20210002226-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2021-01-07 | — | — | US | claimed |
| US-20200390757-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2020-12-17 | — | — | US | claimed |
| WO-2018191474-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | KEMPHARM, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| WO-2018191472-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | KEMPHARM, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2017-11-02 | — | — | US | claimed |
| CN-107261148-A | Methylphenidate prodrug, its preparation and application | 凯姆制药公司 | 2017-10-20 | — | — | CN | claimed |
| EP-3226907-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS AND MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2017-10-11 | — | — | EP | claimed |
| EP-2771002-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| EP-2736510-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2014-06-04 | — | — | EP | claimed |
| CN-103826633-A | Methylphenidate prodrugs, methods of making and using the same | KEMPHARM INC | 2014-05-28 | — | — | CN | claimed |
| US-20130150395-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2013-06-13 | — | — | US | claimed |
| WO-2013063204-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2013016668-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC. (US) | 2013-01-31 | — | — | WO | claimed |
| US-20120142720-A1 | Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof | KEMPHARM, INC. (US) | 2012-06-07 | — | — | US | claimed |
| EP-2448408-A1 | PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID CONJUGATES AND PRODRUGS OF HYDROCODONE, METHODS OF MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2012-05-09 | — | — | EP | claimed |
| WO-2011002995-A1 | PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID CONJUGATES AND PRODRUGS OF HYDROCODONE, METHODS OF MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2011-01-06 | — | — | WO | claimed |
| US-20110002991-A1 | PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID CONJUGATES AND PRODRUGS OF HYDROCODONE, METHOD OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2011-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142720-A1 | Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof | CYP7A1, CYP2B6, CYP2D6 | CA1 1673/4885CA2 2983/4885CA4 2463/4885 |
| US-20200390757-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | CA1 1503/4885CA2 3018/4885CA4 2502/4885 |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, OPRD1 | CA1 1451/4885CA2 1603/4885CA4 2120/4885 |
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | OPRM1, OPRL1, OPRK1 | CA1 1503/4885CA2 3018/4885CA4 2502/4885 |
| US-20110002991-A1 | PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID CONJUGATES AND PRODRUGS OF HYDROCODONE, METHOD OF MAKING AND USE THEREOF | CYP7A1, CYP2B6, CYP2D6 | CA1 1750/4885CA2 3052/4885CA4 2548/4885 |
| US-11234975-B2 | Levorphanol prodrugs and processes for making and using them | OPRM1, OPRL1, OPRK1 | CA1 1503/4885CA2 3018/4885CA4 2502/4885 |
| US-20210002226-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRK1, OPRD1 | CA1 1583/4885CA2 2763/4885CA4 2211/4885 |
| US-20130150395-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, CYP2D6 | CA1 1329/4885CA2 2379/4885CA4 2484/4885 |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | CA1 1503/4885CA2 3018/4885CA4 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.